Showing 4041-4050 of 9737 results for "".
- Skin Cancer Champions Hosts Event to Brainstorm for Growth, Sustainabilityhttps://practicaldermatology.com/news/Skin-Cancer-Champions-Hosts-Event-Brainstorm-Growth-Sustainability/2471116/The Skin Care Champions nonprofit hosted an innovation tournament at Brigham and Women’s Hospital on February 3, bringing together clinicians, patients, caregivers, industry, and more to brainstorm ideas for the organization to achieve growth and sustainability in the future. Emily S. Ruiz
- LEO Pharma Set for Five Late-Breaking Presentations at EADVhttps://practicaldermatology.com/news/leo-pharma-set-five-late-breaking-presentations-eadv/2468299/LEO Pharma A/S will present new clinical and real-world data from across its portfolio of products at the 33rd European Academy of Dermatology and Venereology (EADV) Congress from September 25-28 in Amsterdam, Netherlands, the company announced. Five coveted late-breaking presentations wi
- CHE Studies Presented at ESCD 2024 Congresshttps://practicaldermatology.com/news/che-studies-presented-escd-2024-congress/2468089/LEO Pharma A/S presented a range of new population-level and physician-reported data on the prevalence, severity, and treatment of moderate-to-severe chronic hand eczema (CHE). The data forms part of an expansive scientific program from LEO Pharma. Eight posters in total will be shared at the Eur
- Almirall Announces New Sustainability Strategyhttps://practicaldermatology.com/news/almirall-announces-new-sustainability-strategy/2467252/The five pillars of Planet, People, Patients, Partners, and Principles are at the center of Almirall S.A.’s new sustainability strategy, Act4Impact 2030, the company announced. The updated strategy aims at transforming the company’s sustainability roadmap and consists of 20 strategic lines
- Evaxion’s AI-Powered Cancer Vaccine Demonstrates High Response in Early Studyhttps://practicaldermatology.com/news/evaxions-ai-powered-cancer-vaccine-demonstrates-high-efficacy-in-early-study/2467073/Evaxion Biotech A/S, a firm specializing in AI-driven immunology vaccines, recently published data from its Phase 1 dose escalation study of the EVX-01 personalized cancer vaccine for metastatic melanoma showing almost 70% clinical response from patients. The study, published in the J
- New Image-Guided Dermatology Therapy System Receives CE Mark in Europehttps://practicaldermatology.com/news/new-oncology-and-dermatology-device-approved-europe/2463232/Ultrasound tech manufacturer TOOsonix A/S announced that it has received EU Medical Device Regulation (MDR) CE certification for its image-guided dermatologic therapy system, System ONE-M™, according to a news release from the company. The device facilitates the treatment of common skin c
- Impact of Alopecia Areata on Pediatric Patients and Their Families: Insights from a Single-Center Study in Turkeyhttps://practicaldermatology.com/news/impact-alopecia-areata-pediatric-patients-and-their-families-insights-single-center-study-turkey/2462829/Alopecia areata (AA) is known to impact the health-related quality of life (HRQoL) of affected individuals, yet there is a paucity of research focusing on its effects specifically in pediatric patients and their families. To address this gap, researchers recently conducted a single-center cross-s
- Micro-Coring Could Offer Nonsurgical Option for Moderate to Severe Rhytidshttps://practicaldermatology.com/news/micro-coring-offers-nonsurgical-option-moderate-severe-rhytids/2462726/A dermal micro-coring device improved the appearance of moderate-to-severe rhytids on the cheek and lower face after two treatments, according to data from a new study presented at the American Society for Laser Medicine and Surgery 43rd Annual Conference on Energy-based Medicine and S
- Galderma to Showcase Latest Updates From Its Dermatology Portfolio at the 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/galderma-to-showcase-latest-updates-from-its-dermatology-portfolio-at-the-2024-american-academy-of-dermatology-annual-meeting-1/2462259/Galderma will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) annual meeting from March 8-12, 2024, highlighting its dermatology portfolio. Galderma’s presence includes two late-breaking presentations on its first-in-class, investi
- Bimekizumab Shown Safe at 3 Years for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/bimekizumab-shown-safe-at-3-years-for-moderate-to-severe-plaque-psoriasis/2462216/In a poster presented at Maui Derm, 2024, results from a long-term pooled analysis from five phase-3/3b trials indicate that bimekizumab (BKZ) is safe and well-tolerated at the 3-year mark in patients with moderate-to-s